Inhibitors of isoprenylcysteine carboxyl methyltransferase
The present invention relates, in general, to isoprenylcysteine carboxyl methyltransferase (Icmt) and, in particular, to inhibitors of Icmt and to methods of disease treatment using same.
1. A compound of Formula I:
wherein R 1 is:
an alkyl, substituted or unsubstituted,
a (CH 2 ) n -substituted or unsubstituted aryl, n being an integer between 0 and 6, or
a (CH 2 ) n —O-substituted or unsubstituted aryl, n being an integer between 0 and 6, and
wherein R 2 is a (CH 2 ) m -substituted or unsubstituted aryl, m being an integer between 0 and 4; or
pharmaceutically acceptable salt thereof.
2. The compound according to claim 1
wherein R 1 is:
a C 1 -C 20 alkyl, substituted or unsubstituted,
a —(CH 2 ) n -phenyl or —(CH 2 ) n -napthyl, substituted or unsubstituted, n being an integer between 1 and 4, or
a —(CH 2 ) n —O-phenyl or (CH 2 ) n —O-napthyl, n being an integer between 1 and 4, and
wherein R 2 is a (CH 2 ) m -phenyl, wherein said phenyl is unsubstituted or substituted with at least one halogen, at least one unsubstituted or substituted alkyl or at least one —O—Y wherein Y is a C 1 -C 4 alkyl or an aryl, m being an integer between 0 and 4; or
pharmaceutically acceptable salt thereof.
3. A compound of Formula I:
wherein R 1 is:
a linear, branched or cyclic C 4 -C 15 alkyl,
a (CH 2 ) n -phenyl wherein said phenyl is unsubstituted or meta or para substituted with at least one branched C 4 unsubstituted alkyl or a CX 3 , wherein X is a halogen, n being an integer between 1 and 4, or
a (CH 2 ) n —O-phenyl wherein said phenyl is unsubstituted or meta or para substituted with at least one branched C 4 unsubstituted alkyl or a CX 3 , wherein X is a halogen, n being an integer between 1 and 4, and
wherein R 2 is a (CH 2 ) m -phenyl wherein said phenyl is unsubstituted or substituted with at least one halogen, at least one CX 3 , wherein X is a halogen, or at least one —O—Y wherein Y is a C 1 -C 4 alkyl or phenyl, substituted or unsubstituted, m being an integer between 0 and 4; or
pharmaceutically acceptable salt thereof.
4. The compound according to claim 3 wherein said compound is selected from the group consisting of
5. The compound according to claim 3 wherein said compound is
6. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition according to claim 6 wherein said composition is in the form, of a sterile solution.
8. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier.
9. A method of treating colo-rectal cancer comprising administering to a mammal in need thereof a compound of Formula I
wherein R 1 is:
an alkyl,
a (CH 2 ) n -substituted or unsubstituted aryl, n being an integer between 0 and 6, or
a (CH 2 ) n —O-substituted or unsubstituted aryl, n being an integer between 0 and 6, and
wherein R 2 is a (CH 2 ) m -substituted or unsubstituted aryl, m being an integer between 0 and 4; or
pharmaceutically acceptable salt thereof, in an amount sufficient to effect said treatment.
10. The method according to claim 9 wherein said mammal is a human.
11. A method of inhibiting Icmt-catalyzed CaaX protein methylation in a mammal comprising administering to a mammal in need thereof an amount of a compound of Formula I
wherein R 1 is:
an alkyl,
a (CH 2 ) n -substituted or unsubstituted aryl, n being an integer between 0 and 6, or
a (CH 2 ) n —O-substituted or unsubstituted aryl, n being an integer between 0 and 6, and
wherein R 2 is a (CH 2 ) m -substituted or unsubstituted aryl, m being an integer between 0 and 4; or
pharmaceutically acceptable salt thereof, in an amount sufficient to effect said inhibition.
12. The method according to claim 11 wherein said mammal is a human.
13. The method according to claim 11 wherein said mammal has colo-rectal cancer.